What is the pharmacology and recommended dosing regimen of vonoprazan?

Vonoprazan Pharmacology and Dosing

Vonoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly binds to the H+/K+-ATPase proton pump, providing rapid, potent, and prolonged gastric acid suppression with a half-life of 6-9 hours, and is dosed at 10-20 mg once daily for most indications or 20 mg twice daily for H. pylori eradication. 1, 2

Pharmacological Characteristics

Mechanism of Action

Vonoprazan differs fundamentally from PPIs in several key ways 1:

• Reversible ionic binding to the potassium-binding site of H+/K+-ATPase (versus irreversible covalent binding of PPIs)
• Not a prodrug - does not require acid activation, enabling immediate effect
• Acid-stable - maintains activity in acidic environments
• Approximately 350 times more potent than lansoprazole at inhibiting H+/K+-ATPase 3

Pharmacokinetics

Absorption and Distribution 2, 3:

• Tmax: 1.5-2.0 hours (median 2.0 hours at 20 mg once daily)
• Food effect: Minimal (5% increase in Cmax, 15% increase in AUC) - can be taken without regard to meals
• Protein binding: 85-88%
• Volume of distribution: 1050-1270 L (extensive tissue distribution)
• Steady state: Achieved by Day 3-4

Metabolism and Elimination 2, 3:

• Metabolized by multiple CYP isoforms (CYP3A4/5, CYP2B6, CYP2C19, CYP2C9, CYP2D6) plus sulfotransferases and glucuronosyltransferases
• CYP2C19 polymorphisms have minimal clinical impact (only 15-29% variation in exposure) - major advantage over PPIs
• Half-life: 6.8-7.9 hours (versus 1-2 hours for PPIs)
• Excretion: 67% in urine (8% unchanged), 31% in feces (1.4% unchanged)

Special Populations 2:

• Renal impairment: AUC increased 1.3-2.4× (mild to severe); no dose adjustment typically needed
• Hepatic impairment: AUC increased 1.2-2.6× (mild to severe); use caution with moderate-severe impairment
• Geriatric: No clinically meaningful differences
• Sex/Race: No significant differences

Pharmacodynamics

Acid Suppression Profile 1, 4:

• Achieves intragastric pH >4 within 4 hours of first dose
• Day 1: pH >4 holding time ratio (HTR) ~64%, pH >6 HTR ~30%
• Day 7: pH >4 HTR 83-90%, pH >6 HTR 53-75% (dose-dependent)
• Maintains target pH for longer proportions of 24-hour period than PPIs
• Maximal acid suppression achieved in 1 day (versus 3-5 days for PPIs)

Gastrin Effects 2:

• Mean fasting gastrin levels increase from baseline by Week 2
• Levels remain elevated during treatment
• Return to normal within 4 weeks of discontinuation
• Causes enterochromaffin-like (ECL) cell hyperplasia (expected pharmacologic effect)
• No neoplastic changes observed in patients treated up to 260 weeks

---

Dosing Regimens by Indication

Erosive Esophagitis (EE)

Healing Phase 1, 2:

• LA Grade A/B: 20 mg once daily for 8 weeks
• LA Grade C/D: 20 mg once daily for 8 weeks
• Can be taken without regard to meals

Maintenance Phase 1, 2:

• LA Grade A/B: 10 mg once daily for up to 24 weeks
• LA Grade C/D: 10-20 mg once daily for up to 24 weeks
  • 10 mg provides 75% maintenance of healing
  • 20 mg provides 77% maintenance of healing (versus 62% with lansoprazole 15 mg)

Clinical Context: Vonoprazan demonstrates superiority over lansoprazole 15 mg specifically for LA Grade C/D maintenance, with recurrence rates of 5-13% versus 39% 1. For LA Grade A/B, efficacy is similar to PPIs, making vonoprazan most appropriate for PPI failures or severe disease.

Non-Erosive Reflux Disease (NERD)

Dosing 1, 5:

• 10 mg once daily or 20 mg once daily for 4 weeks initially
• Both doses show similar efficacy (44.8% vs 44.4% heartburn-free days)
• Benefit begins as early as Day 1 (8-12% more heartburn-free days than placebo)
• Can extend to 24 weeks for maintenance

Clinical Context: Use primarily for PPI-refractory NERD with documented acid-related reflux (pH monitoring showing esophageal acid exposure >6%) 1.

Helicobacter pylori Eradication

Standard Triple Therapy 1:

• Vonoprazan 20 mg twice daily + clarithromycin + amoxicillin for 14 days
• Achieves 92% eradication versus 80% with PPI-based therapy
• Superior for clarithromycin-resistant strains: 66-70% versus 32% with PPIs

Dual Therapy (Alternative) 1:

• Vonoprazan 20 mg twice daily + amoxicillin 750 mg twice daily for 7 days
• Achieves 85% eradication
• Particularly effective for clarithromycin-resistant strains: 92% eradication

Shortened Regimen 1:

• Vonoprazan 20 mg twice daily-based triple therapy for 7 days achieves 87% eradication (similar to 14-day PPI regimens)

Clinical Context: Vonoprazan should be used in place of PPIs for most H. pylori eradication 1. The twice-daily dosing is critical for optimal efficacy, particularly in resistant infections.

Peptic Ulcer Disease

Treatment 1:

• Gastric ulcers: 20 mg once daily for 8 weeks (94% healing)
• Duodenal ulcers: 20 mg once daily for 6 weeks (96% healing)

Clinical Context: Efficacy is similar to lansoprazole 30 mg, so vonoprazan is generally not first-line due to higher cost, but appropriate for PPI failures 1.

On-Demand Therapy

Dosing 1:

• 20 mg as needed for heartburn episodes
• Provides complete relief within 3 hours in 56-70% of episodes (versus 27% with placebo)
• Relief begins within 1 hour

---

Key Clinical Considerations

Advantages Over PPIs

• No meal timing required (versus 30-60 minutes before meals for PPIs) 1
• Faster onset (maximal suppression Day 1 versus Days 3-5) 1
• More consistent acid suppression regardless of CYP2C19 genotype 1, 3
• Longer duration of action (half-life 6-9 hours versus 1-2 hours) 1

When to Use Vonoprazan

Should be used 1:

• H. pylori eradication (most patients)
• LA Grade C/D EE that fails PPI maintenance therapy

May be used 1:

• PPI-refractory GERD with confirmed acid-related disease (LA Grade B+ EE, Barrett's, peptic stricture, or pH monitoring showing acid exposure >6%)
• LA Grade C/D EE as initial therapy (though cost may limit routine first-line use)

Generally should not be first-line 1:

• Uninvestigated heartburn
• Non-erosive GERD without PPI trial
• LA Grade A/B EE
• Peptic ulcer disease (unless PPI failure)

Safety Monitoring

• Monitor for gastrin elevation (expected, reversible) 2
• ECL cell hyperplasia is expected pharmacologic effect 2
• No neoplastic changes observed through 260 weeks 2
• Increased infection risk (similar to PPIs) due to potent acid suppression 1

Drug Interactions

• Clarithromycin co-administration: Increases vonoprazan AUC by 1.8× and clarithromycin AUC by 1.5× (mutual CYP3A4 inhibition) 3
• Less affected by CYP2C19 polymorphisms than PPIs 1, 3